Abstract
Correlates of neuroleptic response latency were assessed in 16 male schizophrenic inpatients during 4 weeks of fixed dose (20 mg/day) haloperidol treatment. Rapid responders showed a mean 40% reduction in Brief Psychiatric Rating Scale (BPRS) positive symptom scores by day 10 of treatment. Rapid responders had significantly lower plasma homovanillic acid (pHVA) concentrations compared to non-rapid responders during week 4 of haloperidol treatment. However, rapid versus non-rapid responders did not differ with respect to demographics, baseline positive or negative BPRS symptom scores, performance on tests of neuropsychological function, or mean plasma haloperidol concentrations.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 171-177 |
| Number of pages | 7 |
| Journal | Psychiatry Research |
| Volume | 33 |
| Issue number | 2 |
| DOIs | |
| State | Published - Aug 1990 |
Funding
Acknowledgments. This work was supported in part by grants from the National Institute of Mental Health, MH-30854 to the VA-Stanford Mental Health Clinical Research Center at Stanford University, and a special grant of the Medical Research Service of the Veterans Administration (now Department of Veterans Affairs) to the Schizophrenia Biologic Research Center (SBRC) at the Palo Alto VA Medical Center. The authors thank Elizabeth Mahler for her assistancei n the review of the literature and Pamela J. Elliott for manuscript preparation and editorial advice.
Keywords
- Homovanillic acid
- haloperidol
- neuropsychology
- schizophrenia
ASJC Scopus subject areas
- Psychiatry and Mental health
- Biological Psychiatry